N/A N=15 Circadian Macular Volume Changes in the Choroid
Choroid Physiology
Primary: Macular Choroidal Volume — 10.33 mm^3
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=22 Sildenafil for Treatment of Choroidal Ischemia
Choroidal Ischemia · Vitelliform Macular Dystrophy · Age-related Macular Degeneration
Primary: Change in Visual Acuity (Sildenafil Group) — 0.00; -0.03 logMAR
Phase 2 N=28 Circadian Rhythms of Aqueous Humor Dynamics in Humans
Glaucoma
Primary: Intraocular Pressure — 17.6; 16.4; 20.2; 17.0 mmHg — p=<.05
N/A N=35 Aqueous Suppressant Versus Aqueous Outflow on Ocular Blood Flow
Glaucoma
Primary: 6-month Change in Ophthalmic Artery (OA) Peak Systolic Velocity (PSV) — -.70; 1.84 cm/sec — p=.4414
Phase 1 N=7 Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
Choroidal Neovascularization
Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…
Phase 4 N=49 Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Exudative Age-related Macular Degeneration
Primary: Caliber of Choroidal New Vessel (CNV) — 43.53 micrometer
Phase 3 N=295 Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular Age-Related Macular Degeneration
Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants
N/A N=66 Physiologic Phacofluidics: Ghost Protocol
Cataract
Primary: Change in Early Post Operative Central Corneal Thickness — 623.9; 650.2 microns
Phase 4 N=333 Aflibercept in Polypoidal Choroidal Vasculopathy
Neovascular Macular Degeneration
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last…
N/A N=46 The Effects of an Antioxidant Formulation on Ocular Blood Flow
Primary Open Angle Glaucoma
Primary: Change in Superior Retinal Capillary Blood Flow (% Zero Pixels) — -0.026; 0.011 % zero pixels — p=0.0016
Phase 4 N=35 Circadian Ocular Perfusion Pressure and Ocular Blood Flow
Glaucoma
Primary: Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6 — 2.6; 0.8 mmHg (millimeters of mercury)
Phase 2 N=6 Choroideremia Gene Therapy Clinical Trial
Choroideremia
Primary: Change in Best Corrected Visual Acuity From Baseline — 3.0 Letters
N/A N=7 Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)
Glaucoma
Primary: Presence of Retinal Vascular Dysregulation (RVD) — 7; 4 Participants
Phase 4 N=35 Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
Glaucoma; Drugs · Normal Tension Glaucoma · Primary Open-angle Glaucoma
Primary: Changes in Vessel Density in Treatment Groups Assessed by OCT Angiography — -0.51; 2.59; -0.96; 0.96 percent change
Phase 3 N=40 Ozurdex for Retinal Vein Occlusion Study (ORVO Study)
Retinal Vein Occlusion
Primary: Number of Participants Who Had a >30% Decrease in the Aqueous Levels of Various Vasoactive Proteins 4 Weeks After an Injection of Ozurdex — 7; 5; 7; 4 participants
Phase 2 N=8 Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Choroidal Melanoma
Primary: To Evaluate the Safety/Efficacy of Intravitreal Injection of High Dose Ranibizumab Combined With TTT + ICG-based Photodynamic Therapy in the Treatment of Choroidal…
Phase 2 N=20 Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
Polypoidal Choroidal Vasculopathy
Primary: Commonly Reported and Notable Adverse Events — 1; 2; 2; 3 participants
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
Phase 3 N=169 Efficacy and Safety of BIIB111 for the Treatment of Choroideremia
Choroideremia
Primary: Percentage of Participants With a ≥15 -Letter Improvement From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 as Measured by the Early Treatment of Diabetic…
N/A N=33 Analysis of the Eye in Patients With Primary Open-Angle Glaucoma and a Visual Field Defect in One Eye
Glaucoma
Primary: Lamina Cribrosa (Boundaries of the Retinal Layers) Measurements — 264.3; 273.3; 276.2 micro-ohms
Phase 4 N=48 Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
Exudative Age-related Macular Degeneration · Polypoidal Choroidal Vasculopathy
Primary: Percentage of Patients Lose Visual Acuity Less Than 15 Letters — 87.5 percentage of patients
N/A N=100 Evaluation of Retinal Microvascular Change That May Develop in After Open Globe Injury
Eye Injury Trauma
Primary: Corneal Thickness — 542.23; 546.16; 544.32 microns
Phase 3 N=49 A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)
Chorioretinal Vascular Disease
Primary: Percentage of IVT Injections Successfully Administered — 100; 100 Percentage of Successful Injections
Phase 3 N=200 A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
Choroidal Neovascularization Secondary to Pathologic Myopia
Primary: Number of Patients Treated and Re-treated Based on Presence/Absence of Active Leakage — 3; 0; 61; 121 Patients — p=<0.0001
Phase 3 N=321 Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
Macular Degeneration · Choroidal Neovascularization
Primary: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12 — 53.7; 54.6; 54.8; 59.0 Letters
Phase 3 N=277 Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Pathological Myopia
Primary: Average Change From Baseline to Month 1 Through Month 3 on Visual Acuity of the Study Eye — 55.4; 55.8; 54.7; 66.0 Letters
N/A N=218 Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications
Uveitis · Iritis · Iridocyclitis
Primary: Macular Thickness Measured With the OCT; in Relation to Age, Sex, Reproductive Factors and the Use of Anti-inflammatory Eye Drops in Health; in Uncomplicated Anterior…
Phase 3 N=457 Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
Primary: Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3 — 53.7; 54.2; 52.6; 63.1 ETDRS letters — p=<0.001
N/A N=26 Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Age-related Macular Degeneration
Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05
Phase 4 N=61 Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
Polypoidal Choroidal Vasculopathy
Primary: Number of Participants With Complete Regression (CR) of Polyps Measured by Indocyanine Green Angiography (ICGA) — 14; 15; 6 Participants